Molecular Epidemiology ; trends

?AlM:To explore the use of rigid gas permeable ( RGP ) contact lens, and its clinical effect and safety in the treatment of adult high and special type ametropia.
? METHODS: Totally 110 cases ( 185 eyes ) of Ophthalmology Center fitting of RGP from January 2010 to December 2012 were retrospective analyzed. According to the refractive error types, patients were divided into high myopia astigmatism group( 49 cases, 92 eyes), 36 cases (64 eyes) of keratoconus group, special ametropia group (25 cases, 29 eyes). Corrected visual acuity differences, adverse reactions of different temporal acuity and conventional frame in the three group were observed after wearing RGP.
?RESULTS:After wearred RGP, corrected visual acuity of high myopic astigmatism group was 4. 94 ± 0. 16, keratoconus group was 4. 98±0. 15, and special ametropia group was 4. 87±0. 19; they were significantly better than wearing frame mirror 4. 86±0. 23, 4. 79±0. 22, 4. 61±0. 27 and the differences were statistically significant (P<0. 05). After 3 and 6mo of wearing RGP, patients eyesight after RGP was better than that of wearing frame glasses ( P<0. 05 ) . As the astigmatism group, keratoconus group, special ametropia group wearing RGP, visual acuity after distribution were obviously better than the case when wearing frame glasses(P<0. 05).
?CONCLUSlON: Wearring RGP can correct adult high and special type ametropia than ordinary frame glasses, which avoid the occurence of dry eye, foreign body sensation, and easy fatigue. lt is worthy of clinical application.

Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Neoplastic Stem Cells ; Pyrazoles ; Pyrimidines

Antineoplastic Agents ; pharmacology ; therapeutic use ; Benzamides ; Clinical Trials, Phase II as Topic ; Drug Resistance, Neoplasm ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; drug therapy ; Piperazines ; pharmacology ; therapeutic use ; Pyrimidines ; pharmacology ; therapeutic use

Objective:To observe the effect of point-toward-point needling at points on the low back regions on residual back pain after percutaneous kyphoplasty (PKP),thoracolumbar function and quality of life (QOL) in patients with osteoporotic vertebral compression fracture (OVCF).Methods:A total of 72 patients with OVCF and residual back pain after PKP were included and allocated into a treatment group (n=36) and a control group (n=36) by the random number table.Cases in the control group received salmon calcitonin injection (miacalcic),for 1 mL each time,once a day,and oral intake of calcium carbonate D3 pill,600 mg each time,once a day,whereas cases in the treatment group received point-toward-point needling at points on the low back regions and electroacupuncture (EA) for 30 min each time,once a day and 6 times a week on the basis of the treatment in the control group.Treatment in both groups lasted for 2 weeks.Therapeutic efficacy indicators including visual analog scale (VAS),Oswestry disability index (ODI) and Barthel index (BI) were evaluated before and after treatment and at follow-up visit (1 month after treatment).Results:The total effective rate was 94.4％ and 88.9％ in the treatment group after treatment and at the follow-up visit,respectively,higher than 77.8％ and 69.4％ in the control group,and the between-group differences were statistically significant (both P＜0.05).After treatment and at the follow-up visit,the VAS and ODI scores decreased,and BI scores increased in both groups,and the intra-group differences were statistically significant (all P＜0.05).After treatment and at the follow-up visit,between-group differences of VAS,ODI and BI scores were statistically significant (all P＜0.05).Conclusion:On the basis of conventional medication treatment,point-toward-point needling at points on the low back regions has a good therapeutic effect in relieving residual back pain after PKP,improving thoracolumbar function and QOL,better than conventional medication treatment alone.

Objective:To explore the stratege of teratoma treatment in individual patient.Methods:53 cases(40 benign and 13 malignant) with teratoma were admitted from January 2001 to October 2003.Benign teratomas were treated with individual operation process in order to resect the whole tumor and to keep the function of the organ.In malignant teratoma chemotherapy was given before operation,then,tumor resection,and individual chemotherapy after operation.Results:40 benign cases treated with operation were all successful without complications except 3 newborn babies with low serum albumin and delayed wound healing.In 13 malignant cases,5 abdicated chemotherapy and 8 succeeded continuously with individual chemotherapy postoperation.Until now:initial lose to follow -up 5 examples,midway lose to follow -up 2 examples,PR3,CR3.Conclusion:It's important that the individual treatment of teratoma,especially individual chemotherapy against malignant teratoma can improve quality of life and increase cure rate in children with tumor.

Objective:To construct an eukaryotic coexpression plasmid containing Mycobacterium tuberculosis Ag85B and MPT64 gene.Methods:Mycobacterium tuberculosis Ag85B and MPT64 gene were cloned into pBudCE4.1 to construct recombinant plasmid pBud85B-MPT.The recombinant plasmid was transfected into COS-7 cells,and its expression of Ag85B and MPT64 was assesed by RT-PCR.Results:Mycobacterium tuberculosis Ag85B and MPT64 were detected in transfected COS-7 cells.Conclusion:The recombinant plasmid pBud85B-MPT can express Ag85B and MPT simultaneously in COS-7 cells which provides the basis for further investigation of DNA vaccine against tuberculosis.

Objective:To transfer full-length human mdrlcDNA into K562 cells and assess the feasibility and safety in vitro.Methods:PA317 cells were transducted via a virus vector,pHaMDR1/A,containing full-length human mdr1cDNA by calcium phosphate precipitation.The K562 cells were infected with the virus supernatant.The transfection rate was determined by using CFU selection,FACS and SP immunohistochemical methods respectively.The foreign Pgp function was tested by MTT assay and DNR exclusion with FACS analysis .The cellular cycle and the expression of bcl-2 and c-myc gene were detected by using CFU sclcction,FACS and SP immunohistochemical mcthods respcctively.The forcign Pgp function was tested by MTT assay and DNR exclusion with FACS analysis.The cellular cycle and the expression of bcl-2 and c-myc gene were detected by using PI via FCM and SP stain respectively.These data were analyzed with statistic graph and T-test for match pairs.Results:①The highest transfection rate of K562/MDR6-18 cells were 34%,even up to 84% after colchicine selection.②The exogenous Pgp expression of K562/MDR6-18 cells lasted for more than 4 months with a slow decrease after 10 generations.③The exogenous Pgp got an exclusive pump function.④K562/MDR6-18 cells appeared 1.46-2.22 times cross multidrug resistance phenotype.⑤K562/MDR6-18 cellular proliferation showed a mild,short,restored change.There was no abnormal apoptosis or proliferation.Conclusions:It implies a feasible,attractive and safe way that mdr1 gene transfers into target cells to get exogenous effective MDR.They also provide the basic protocol for using mdr1 gene modifying bone marrow transplantation against the myelosuppressive effects of anticancer drugs.

In order to contribute to engineering for QOL, dualism of universal design (UD) and orphan products (OP) is discussed. UD is for larger market size without adaptation, and OP is for smaller market size with extensive adaptation. In this model of assistive products (AP), AP is in a spectrum of UD and OP at both extremes. Definitions of AP by ISO and by ICF are discussed and the difference is illustrated using this model. The position of AP in the spectrum shows expected market size and degree of necessary adaptation. R&D aspects of AP are also discussed. Technology transfer from mainstream is beneficial to AP. A hypothesis is presented that AP tend to move towards UD extreme on the spectrum, if it is relevant to environment.